Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I5JM
|
||||
| Former ID |
DIB015905
|
||||
| Drug Name |
LC-350189
|
||||
| Indication | Gout [ICD9: 274.00274.1274.8274.9; ICD10:M10] | Phase 1 | [1] | ||
| Target and Pathway | |||||
| Target(s) | Xanthine dehydrogenase/oxidase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Purine nucleotides degradation | ||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Retinoate biosynthesis II | |||||
| KEGG Pathway | Purine metabolism | ||||
| Caffeine metabolism | |||||
| Drug metabolism - other enzymes | |||||
| Metabolic pathways | |||||
| Peroxisome | |||||
| PANTHER Pathway | Adenine and hypoxanthine salvage pathway | ||||
| Purine metabolism | |||||
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Purine Metabolism | |||||
| Reactome | Purine catabolism | ||||
| WikiPathways | Oxidative Stress | ||||
| Effects of Nitric Oxide | |||||
| Metabolism of nucleotides | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01361646) Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189. U.S. National Institutes of Health. | ||||
| REF 2 | Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.